LMU Medizinische Fakultät IBE IBE
Suche:
Home  |  Sitemap  |  RSS RSS  |  www.lmu.de  |  Medizinische Fakultät  |  LMU-Portal
IBE - Institut für medizinische Informationsverarbeitung, Biometrie und Epidemiologie
Pfirrmann

Hr. Dr. rer. biol. hum. Markus Pfirrmann, M.Sc.

Drittmittel
KONTAKT
IBE - Marchioninistr. 15, 81377 München
Telefon: +49 (0)89 / 4400 - 77489
E-Mail: E-Mail pfi@ibe.med.uni-muenchen.de

Zimmer: K U1 842
Kurzlebenslauf

1987-1993 Studium der Statistik an der Ludwig-Maximilians-Universität in München

1993-1994 Master of Science in "Applied Stochastic Systems" am University College London

1995-1997 Wissenschaftlicher Mitarbeiter am IBE

1997-1998 Projektleiter am BZT Biometrisches Zentrum für Therapiestudien, München

1998-2007 Projektleiter an der GIS Gesellschaft für Informationsverarbeitung und Statistik in der Medizin e.V.

Im Jahre 2000 Verleihung des Paul-Martini-Preis der Deutschen Gesellschaft für Medizinische Informatik, Biometrie und Epidemiologie, GMDS e.V.

2007: Promotion am IBE

Seit 2007 wissenschaftlicher Mitarbeiter am IBE

Arbeitsbereiche
  • Methodik, Planung und Auswertung klinischer Studien
  • Prognoseforschung
  • Überlebenszeitanalyse
  • Analyse konkurrierender Ereignisse
Projekte
  • Projektmanagement und methodische Betreuung von sechs Studien aus der chronischen myeloischen Leukämie (CML), von zwei "AML (akute myeloische Leukämie) Intergroup“-Studien zur Therapieoptimierung und Prognoseforschung aus dem Kompetenznetz „Akute und Chronische Leukämien“, der Germain-Studie zum Multiplen Myelom und der Europe Stops Tyrosine Kinase Inhibitors (Euro-SKI)-Studie. Studienkoordination, Kommunikation mit externen und internen Partnern und Mitarbeitern
  • Kooperation mit klinischen Kollegen in einzelnen Projekten mit besonderer Fragestellung
  • Prognoseforschung im Rahmen des European Treatment and Outcome Study (EUTOS)-Registers, einem Register imatinib-behandelter CML-Patienten
  • Wissenschaftliche Beratung von Projekten aus dem Klinikum und von medizinischen Doktorarbeiten
Lehrtätigkeit
Dozent bei den Seminaren zu den MeCuM Modulen L5 und L6
Publikationen

Kalmanti L, Saussele S, Lauseker M, Muller MC, Dietz CT, Heinrich L, Hanfstein B, Proetel U, Fabarius A, Krause SW, Rinaldetti S, Dengler J, Falge C, Oppliger-Leibundgut E, Burchert A, Neubauer A, Kanz L, Stegelmann F, Pfreundschuh M, Spiekermann K, Scheid C, Pfirrmann M, Hochhaus A, Hasford J, Hehlmann R. Safety and efficacy of imatinib in CML over a period of 10 years: data from the randomized CML-study IV. Leukemia. 2015.

Pfirrmann M, Lauseker M, Hoffmann V, Hasford J. Prognostic scores for patients with chronic myeloid leukemia under particular consideration of competing causes of death. Annals of Hematology. 2015 April;94(2):209-18.

Lauseker M, Hasford J, Hoffmann V, Müller M, Hehlmann R, Pfirrmann M. A multi-state model approach for prediction in chronic myeloid leukaemia. Ann Hematol. Epub ahead of print 2014 Dec; 1-9. doi:10.1007/s00277-014-2246-2.

Lauseker M, Hanfstein B, Haferlach C, Schnittger S, Pfirrmann M, Fabarius A, Schlegelberger B, Saussele S, Dietz CT, Erben P, Hehlmann R, Hasford J, Hochhaus A, Muller MC. Equivalence of BCR-ABL transcript levels with complete cytogenetic remission in patients with chronic myeloid leukemia in chronic phase. J Cancer Res Clin Oncol. 2014 Nov;140 (11):1965-69.

Hanfstein B, Shlyakhto V, Lauseker M, Hehlmann R, Saussele S, Dietz C, Erben P, Fabarius A, Proetel U, Schnittger S, Krause SW, Schubert J, Einsele H, Hanel M, Dengler J, Falge C, Kanz L, Neubauer A, Kneba M, Stegelmann F, Pfreundschuh M, Waller CF, Spiekermann K, Baerlocher GM, Pfirrmann M, Hasford J, Hofmann WK, Hochhaus A, Muller MC. Velocity of early BCR-ABL transcript elimination as an optimized predictor of outcome in chronic myeloid leukemia (CML) patients in chronic phase on treatment with imatinib. Leukemia. 2014 Oct;28(10):1988-92.

Hehlmann R, Hasford J, Pfirrmann M, Lauseker M, Saussele S, Hochhaus A. Reply to H. Kantarjian et al. J Clin Oncol. 2014 Sep 20;32(27):3078-9

Hanfstein B, Lauseker M, Hehlmann R, Saussele S, Erben P, Dietz C, Fabarius A, Proetel U, Schnittger S, Haferlach C, Krause SW, Schubert J, Einsele H, Hanel M, Dengler J, Falge C, Kanz L, Neubauer A, Kneba M, Stegelmann F, Pfreundschuh M, Waller CF, Spiekermann K, Baerlocher GM, Pfirrmann M, Hasford J, Hofmann WK, Hochhaus A, Muller MC. Distinct characteristics of e13a2 versus e14a2 BCR-ABL1 driven chronic myeloid leukemia under first-line therapy with imatinib. Haematologica. 2014 Sep; 99(9):1441-7.

Pfirrmann M, Saussele S, Hochhaus A, Reiter A, Berger U, Hossfeld DK, Nerl C, Scheid C, Spiekermann K, Mayer J, Hellmann A, Lechner K, Falge C, Sayer HG, Bunjes D, Ganser A, Beelen DW, Baldomero H, Schanz U, Heimpel H, Kolb HJ, Hasford J, Gratwohl A, Hehlmann R. Explaining survival differences between two consecutive studies with allogeneic stem cell transplantation in patients with chronic myeloid leukemia. J Cancer Res Clin Oncol. 2014 Aug;140(8):1367-81.

Proetel U, Pletsch N, Lauseker M, Müller M, Hanfstein B, Krause S, Kalmanti L, Schreiber A, Heim D, Baerlocher G, Hofmann W-K, Lange E, Einsele H, Wernli M, Kremers S, Schlag R, Müller L, Hänel M, Link H, Hertenstein B, Pfirrmann M, Hochhaus A, Hasford J, Hehlmann R, Saußele S. Older patients with chronic myeloid leukemia (≥65 years) profit more from higher imatinib doses than younger patients: a subanalysis of the randomized CML-Study IV. Ann Hematol. 2014 Jul; 93(7):1167-76.

Lauseker M, Hasford J, Pfirrmann M, Hehlmann R. The impact of health care settings on survival time of patients with chronic myeloid leukemia. Blood. 2014 Apr;123(16):2494-6.

Hehlmann R, Muller MC, Lauseker M, Hanfstein B, Fabarius A, Schreiber A, Proetel U, Pletsch N, Pfirrmann M, Haferlach C, Schnittger S, Einsele H, Dengler J, Falge C, Kanz L, Neubauer A, Kneba M, Stegelmann F, Pfreundschuh M, Waller CF, Spiekermann K, Baerlocher GM, Ehninger G, Heim D, Heimpel H, Nerl C, Krause SW, Hossfeld DK, Kolb HJ, Hasford J, Saussele S, Hochhaus A. Deep molecular response is reached by the majority of patients treated with imatinib, predicts survival, and is achieved more quickly by optimized high-dose imatinib: results from the randomized CML-study IV. J Clin Oncol. 2014 Feb 10;32(5):415-23

Kalmanti L, Saussele S, Lauseker M, Proetel U, Muller MC, Hanfstein B, Schreiber A, Fabarius A, Pfirrmann M, Schnittger S, Dengler J, Falge C, Kanz L, Neubauer A, Stegelmann F, Pfreundschuh M, Waller CF, Spiekermann K, Krause SW, Heim D, Nerl C, Hossfeld DK, Kolb HJ, Hochhaus A, Hasford J, Hehlmann R. Younger patients with chronic myeloid leukemia do well in spite of poor prognostic indicators: results from the randomized CML study IV. Ann Hematol. 2014 Jan;93(1):71-80.

Hoffmann VS, Baccarani M, Lindoerfer D, Castagnetti F, Turkina A, Zaritsky A, Hellmann A, Prejzner W, Steegmann JL, Mayer J, Indrak K, Colita A, Rosti G, Pfirrmann M. The EUTOS prognostic score: review and validation in 1288 patients with CML treated frontline with imatinib. Leukemia. 2013 Oct;27(10):2016-22.

Schwaab J, Schnittger S, Sotlar K, Walz C, Fabarius A, Pfirrmann M, Kohlmann A, Grossmann V, Meggendorfer M, Horny HP, Valent P, Jawhar M, Teichmann M, Metzgeroth G, Erben P, Ernst T, Hochhaus A, Haferlach T, Hofmann WK, Cross NC, Reiter A. Comprehensive mutational profiling in advanced systemic mastocytosis. Blood. 2013 Oct 3;122(14):2460-6.

Lange T, Ernst T, Gruber FX, Maier J, Cross M, Muller MC, Niederwieser D, Hochhaus A, Pfirrmann M. The quantitative level of T315I mutated BCR-ABL predicts for major molecular response to second-line nilotinib or dasatinib treatment in patients with chronic myeloid leukemia. Haematologica. 2013 May;98(5):714-7.

Buchner T, Schlenk RF, Schaich M, Dohner K, Krahl R, Krauter J, Heil G, Krug U, Sauerland MC, Heinecke A, Spath D, Kramer M, Scholl S, Berdel WE, Hiddemann W, Hoelzer D, Hehlmann R, Hasford J, Hoffmann VS, Dohner H, Ehninger G, Ganser A, Niederwieser DW, Pfirrmann M. Acute Myeloid Leukemia (AML): Different Treatment Strategies Versus a Common Standard Arm--Combined Prospective Analysis by the German AML Intergroup. J Clin Oncol. 2012 Oct 10;30(29):3604-10.

Hanfstein B, Muller MC, Hehlmann R, Erben P, Lauseker M, Fabarius A, Schnittger S, Haferlach C, Gohring G, Proetel U, Kolb HJ, Krause SW, Hofmann WK, Schubert J, Einsele H, Dengler J, Hanel M, Falge C, Kanz L, Neubauer A, Kneba M, Stegelmann F, Pfreundschuh M, Waller CF, Branford S, Hughes TP, Spiekermann K, Baerlocher GM, Pfirrmann M, Hasford J, Saussele S, Hochhaus A. Early molecular and cytogenetic response is predictive for long-term progression-free and overall survival in chronic myeloid leukemia (CML). Leukemia. 2012 Sep;26(9):2096-102.

Saussele S, Pfirrmann M. Clinical Trials in Chronic Myeloid Leukemia. Current hematologic malignancy reports. 2012 Jun;7(2):109-15.

Lauseker M, Pfirrmann M, Hoffmann VS, Hasford J. Comment on “Second-generation tyrosine kinase inhibitors improve the survival of patients with chronic myeloid leukemia in whom imatinib therapy has failed”. Haematologica. 2012 May 1;97(5):e14-e5.

Hoffmann V, Baccarani M, Hasford J, Guilhot J, Saussele S, Rosti G, Guilhot F, Porkka K, Ossenkoppele G, Lindoerfer D, Simonsson B, Pfirrmann M, Hehlmann R. The EUTOS CML score aims to support clinical decision-making. Blood. 2012 March;119(12):2966-7.

Pfirrmann M, Ehninger G, Thiede C, Bornhauser M, Kramer M, Rollig C, Hasford J, Schaich M. Prediction of post-remission survival in acute myeloid leukaemia: a post-hoc analysis of the AML96 trial. Lancet Oncol. 2012 Feb;13(2):207-14.

Pfirrmann M, Hochhaus A, Lauseker M, Saussele S, Hehlmann R, Hasford J. Recommendations to meet statistical challenges arising from endpoints beyond overall survival in clinical trials on chronic myeloid leukemia. Leukemia. 2011;25(9):1433-8.

Pfirrmann M. Statistisches Testen in der Onkologie. Der Onkologe. 2011;17(4):337-48.

Fabarius A, Leitner A, Hochhaus A, Muller MC, Hanfstein B, Haferlach C, Gohring G, Schlegelberger B, Jotterand M, Reiter A, Jung-Munkwitz S, Proetel U, Schwaab J, Hofmann WK, Schubert J, Einsele H, Ho AD, Falge C, Kanz L, Neubauer A, Kneba M, Stegelmann F, Pfreundschuh M, Waller CF, Spiekermann K, Baerlocher GM, Lauseker M, Pfirrmann M, Hasford J, Saussele S, Hehlmann R. Impact of additional cytogenetic aberrations at diagnosis on prognosis of CML: long-term observation of 1151 patients from the randomized CML Study IV. Blood. 2011 Dec;118(26):6760-8.

Hasford J, Baccarani M, Hoffmann V, Guilhot J, Saussele S, Rosti G, Guilhot F, Porkka K, Ossenkoppele G, Lindoerfer D, Simonsson B, Pfirrmann M, Hehlmann R. Predicting complete cytogenetic response and subsequent progression-free survival in 2060 patients with CML on imatinib treatment: the EUTOS score. Blood. 2011 Jul;118(3):686-92.

Hehlmann R, Lauseker M, Jung-Munkwitz S, Leitner A, Muller MC, Pletsch N, Proetel U, Haferlach C, Schlegelberger B, Balleisen L, Hanel M, Pfirrmann M, Krause SW, Nerl C, Pralle H, Gratwohl A, Hossfeld DK, Hasford J, Hochhaus A, Saussele S. Tolerability-Adapted Imatinib 800 mg/d Versus 400 mg/d Versus 400 mg/d Plus Interferon-alpha in Newly Diagnosed Chronic Myeloid Leukemia. J Clin Oncol. 2011 Apr;29(12):1634-42.

Stolzel F, Pfirrmann M, Aulitzky WE, Kaufmann M, Bodenstein H, Bornhauser M, Rollig C, Kramer M, Mohr B, Oelschlagel U, Schmitz N, Soucek S, Thiede C, Ehninger G, Schaich M. Risk stratification using a new prognostic score for patients with secondary acute myeloid leukemia: results of the prospective AML96 trial. Leukemia. 2011;25(3):420-8.

Saussele S, Lauseker M, Gratwohl A, Beelen DW, Bunjes D, Schwerdtfeger R, Kolb HJ, Ho AD, Falge C, Holler E, Schlimok G, Zander AR, Arnold R, Kanz L, Dengler R, Haferlach C, Schlegelberger B, Pfirrmann M, Muller MC, Schnittger S, Leitner A, Pletsch N, Hochhaus A, Hasford J, Hehlmann R. Allogeneic hematopoietic stem cell transplantation (allo SCT) for chronic myeloid leukemia in the imatinib era: evaluation of its impact within a subgroup of the randomized German CML Study IV. Blood. 2010 Mar;115(10):1880-5.

Schaich M, Kestel L, Pfirrmann M, Robel K, Illmer T, Kramer M, Dill C, Ehninger G, Schackert G, Krex D. A MDR1 (ABCB1) gene single nucleotide polymorphism predicts outcome of temozolomide treatment in glioblastoma patients. Ann Oncol. 2009 Jan;20(1):175-81.

Ernst T, Gruber FX, Pelz-Ackermann O, Maier J, Pfirrmann M, Muller MC, Mikkola I, Porkka K, Niederwieser D, Hochhaus A, Lange T. A co-operative evaluation of different methods of detecting BCR-ABL kinase domain mutations in patients with chronic myeloid leukemia on second-line dasatinib or nilotinib therapy after failure of imatinib. Haematologica. 2009 Sep;94(9):1227-35.

Bruegger D, Rehm M, Abicht J, Paul JO, Stoeckelhuber M, Pfirrmann M, Reichart B, Becker BF, Christ F. Shedding of the endothelial glycocalyx during cardiac surgery: on-pump versus off-pump coronary artery bypass graft surgery. J Thorac Cardiovasc Surg. 2009 Dec;138(6):1445-7.

Kreil S, Pfirrmann M, Haferlach C, Waghorn K, Chase A, Hehlmann R, Reiter A, Hochhaus A, Cross NC. Heterogeneous prognostic impact of derivative chromosome 9 deletions in chronic myelogenous leukemia. Blood. 2007 Aug;110(4):1283-90.

Hehlmann R, Berger U, Pfirrmann M, Heimpel H, Hochhaus A, Hasford J, Kolb HJ, Lahaye T, Maywald O, Reiter A, Hossfeld DK, Huber C, Loffler H, Pralle H, Queisser W, Tobler A, Nerl C, Solenthaler M, Goebeler ME, Griesshammer M, Fischer T, Kremers S, Eimermacher H, Pfreundschuh M, Hirschmann WD, Lechner K, Wassmann B, Falge C, Kirchner HH, Gratwohl A. Drug treatment is superior to allografting as first-line therapy in chronic myeloid leukemia. Blood. 2007 Jun;109(11):4686-92.

Maywald O, Pfirrmann M, Berger U, Breitscheidel L, Gratwohl A, Kolb HJ, Beelen DW, Tobler A, Metzgeroth G, Gnad SU, Hochhaus A, Hasford J, Hehlmann R, Reiter A. Cytogenetic response to prior treatment with interferon-alpha is predictive for survival after allogeneic hematopoietic stem cell transplantation in chronic myeloid leukemia. Leukemia. 2006 Mar;20(3):477-84.

Pfirrmann M, Hasford J. A simulation study using validated prognostic factors to assess expected long-term survival. Methods Inf Med. 2005;44(4):577-83.

Hasford J, Pfirrmann M, Shepherd P, Guilhot J, Hehlmann R, Mahon FX, Kluin-Nelemans HC, Ohnishi K, Steegmann JL, Thaler J. The impact of the combination of baseline risk group and cytogenetic response on the survival of patients with chronic myeloid leukemia treated with interferon alpha. Haematologica. 2005 Mar;90(3):335-40.

Hasford J, Pfirrmann M, Hochhaus A. How long will chronic myeloid leukemia patients treated with imatinib mesylate live? Leukemia. 2005 Apr;19(4):497-9.

Berger U, Maywald O, Pfirrmann M, Lahaye T, Hochhaus A, Reiter A, Hasford J, Heimpel H, Hossfeld DK, Kolb HJ, Loffler H, Pralle H, Queisser W, Hehlmann R. Gender aspects in chronic myeloid leukemia: long-term results from randomized studies. Leukemia. 2005 Jun;19(6):984-9.

Lenz G, Dreyling M, Schiegnitz E, Forstpointner R, Wandt H, Freund M, Hess G, Truemper L, Diehl V, Kropff M, Kneba M, Schmitz N, Metzner B, Pfirrmann M, Unterhalt M, Hiddemann W. Myeloablative radiochemotherapy followed by autologous stem cell transplantation in first remission prolongs progression-free survival in follicular lymphoma: results of a prospective, randomized trial of the German Low-Grade Lymphoma Study Group. Blood. 2004 Nov;104(9):2667-74.

Buesche G, Freund M, Hehlmann R, Georgii A, Ganser A, Hecker H, Heimpel H, Fonatsch C, Heinze B, Pfirrmann M, Holgado S, Schmeil A, Tobler A, Hasford J, Buhr T, Kreipe HH. Treatment intensity significantly influencing fibrosis in bone marrow independently of the cytogenetic response: meta-analysis of the long-term results from two prospective controlled trials on chronic myeloid leukemia. Leukemia. 2004 Sep;18(9):1460-7.

Hehlmann R, Berger U, Pfirrmann M, Hochhaus A, Metzgeroth G, Maywald O, Hasford J, Reiter A, Hossfeld DK, Kolb HJ, Loffler H, Pralle H, Queisser W, Griesshammer M, Nerl C, Kuse R, Tobler A, Eimermacher H, Tichelli A, Aul C, Wilhelm M, Fischer JT, Perker M, Scheid C, Schenk M, Weiss J, Meier CR, Kremers S, Labedzki L, Schmeiser T, Lohrmann HP, Heimpel H. Randomized comparison of interferon alpha and hydroxyurea with hydroxyurea monotherapy in chronic myeloid leukemia (CML-study II): prolongation of survival by the combination of interferon alpha and hydroxyurea. Leukemia. 2003 Aug;17(8):1529-37.

Hasford J, Pfirrmann M, Hehlmann R, Baccarani M, Guilhot F, Mahon FX, Kluin-Nelemans HC, Ohnishi K, Thaler J, Steegmann JL. Prognosis and prognostic factors for patients with chronic myeloid leukemia: nontransplant therapy. Semin Hematol. 2003 Jan;40(1):4-12.

Buesche G, Hehlmann R, Hecker H, Heimpel H, Heinze B, Schmeil A, Pfirrmann M, Gomez G, Tobler A, Herrmann H, Kappler M, Hasford J, Buhr T, Kreipe HH, Georgii A. Marrow fibrosis, indicator of therapy failure in chronic myeloid leukemia - prospective long-term results from a randomized-controlled trial. Leukemia. 2003 Dec;17(12):2444-53.

Berger U, Engelich G, Maywald O, Pfirrmann M, Hochhaus A, Reiter A, Metzgeroth G, Gnad U, Hasford J, Heinze B, Heimpel H, Hossfeld DK, Kolb HJ, Loffler H, Pralle H, Queisser W, Hehlmann R. Chronic myeloid leukemia in the elderly: long-term results from randomized trials with interferon alpha. Leukemia. 2003 Sep;17(9):1820-6.

Pfirrmann M, Hasford J. Testing Sokal's and the new prognostic score for chronic myeloid leukaemia treated with alpha-interferon: comments. Br J Haematol. 2001 Jul;114(1):241-3.

Hasford J, Pfirrmann M, Hehlmann R, Shepherd P, Guilhot F, Mahon FX, Thaler J, Steegmann JL, Kluin-Nelemans HC, Louwagie A, Ohnishi K, Kloke O. Prognostic Factors. In: Carella A, Daley G, Eaves C, Goldman J, Hehlmann R, editors. Chronic Myeloid Leukemia – Biology and Treatment. London: Martin Dunitz; 2001. p. 205-23.

Hehlmann R, Hochhaus A, Kolb HJ, Hasford J, Gratwohl A, Heimpel H, Siegert W, Finke J, Ehninger G, Holler E, Berger U, Pfirrmann M, Muth A, Zander A, Fauser AA, Heyll A, Nerl C, Hossfeld DK, Loffler H, Pralle H, Queisser W, Tobler A. Interferon-alpha before allogeneic bone marrow transplantation in chronic myelogenous leukemia does not affect outcome adversely, provided it is discontinued at least 90 days before the procedure. Blood. 1999 Dec;94(11):3668-77.

Pfirrmann M, Hasford J. Methods for the evaluation and validation of a prognostic score in a data pool of individual data from patients with chronic myeloid leukaemia. In: Greiser E, Wischnewsky M, editors. Methoden der Medizinischen Informatik, Biometrie und Epidemiologie in der modernen Informationsgesellschaft. München: MVV Medizin Verlag; 1998. p. 360-3.

Hasford J, Pfirrmann M, Hehlmann R, Allan NC, Baccarani M, Kluin-Nelemans JC, Alimena G, Steegmann JL, Ansari H. A new prognostic score for survival of patients with chronic myeloid leukemia treated with interferon alfa. Writing Committee for the Collaborative CML Prognostic Factors Project Group. J Natl Cancer Inst. 1998 Jun 3;90(11):850-8.

Hasford J, Ansari H, Pfirrmann M, Hehlmann R. Analysis and validation of prognostic factors for CML. German CML Study Group. Bone Marrow Transplant. 1996 May;17 Suppl 3:S49-54.

Impressum - Datenschutz - Kontakt